Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Panacea Life Sciences Holdings EV-to-EBITDA?
Panacea Life Sciences HoldingsPLSH EV-to-EBITDA is 0.94 as of Jul. 14, 2026. The stock has 10 warning signs investors should review. Among 739 Drug Manufacturers companies, Panacea Life Sciences Holdings ranks better than 96.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Panacea Life Sciences Holdings's enterprise value is $2.35 Mil.
Panacea Life Sciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $2.50 Mil. Therefore, Panacea Life Sciences Holdings's EV-to-EBITDA for today is 0.94.
The historical rank and industry rank for Panacea Life Sciences Holdings's EV-to-EBITDA or its related term are showing as below:
PLSH'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -38.71 Med: -4.98 Max: 7.83
Current: 0.94
During the past 4 years, the highest EV-to-EBITDA of Panacea Life Sciences Holdings was 7.83. The lowest was -38.71. And the median was -4.98.
PLSH's EV-to-EBITDA is ranked better than 96.75% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs PLSH: 0.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Panacea Life Sciences Holdings (OTCPK:PLSH) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panacea Life Sciences Holdings's PE Ratio (TTM) for today is calculated as:
Panacea Life Sciences Holdings's share price for today is $0.10.
Panacea Life Sciences Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Panacea Life Sciences Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panacea Life Sciences Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panacea Life Sciences Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Panacea Life Sciences Holdings's EV-to-EBITDA falls into.
Panacea Life Sciences Holdings's current Enterprise Value is $2.35 Mil.
Panacea Life Sciences Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panacea Life Sciences Holdings (PLSH) has a EV-to-EBITDA of 0.94 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Panacea Life Sciences Holdings. According to the industry distribution chart, Panacea Life Sciences Holdings ranks #24 out of 739 companies in the Drug Manufacturers industry, placing it in the top 3.2%.
Is Panacea Life Sciences Holdings' EV-to-EBITDA too high?
Panacea Life Sciences Holdings' current EV-to-EBITDA is 0.94. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Panacea Life Sciences Holdings' value of 0.94 is 92.8% below this industry median. Based on the distribution chart, Panacea Life Sciences Holdings ranks #24 out of 739 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Panacea Life Sciences Holdings' EV-to-EBITDA compare to SKYI and IMCC?
According to the Drug Manufacturers industry distribution chart, Panacea Life Sciences Holdings ranks #24 out of 739 companies for EV-to-EBITDA. This places Panacea Life Sciences Holdings in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.98. Panacea Life Sciences Holdings' value of 0.94 is 92.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panacea Life Sciences Holdings's current EV-to-EBITDA of 0.94 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Panacea Life Sciences Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panacea Life Sciences Holdings's current EV-to-EBITDA is 0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Life Sciences Holdings stock overvalued right now?
Panacea Life Sciences Holdings (PLSH) has a current EV-to-EBITDA of 0.94. The current EV-to-EBITDA is 0.94 and 92.8% below the Drug Manufacturers industry median of 12.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Panacea Life Sciences Holdings (PLSH), the current EV-to-EBITDA is 0.94 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Panacea Life Sciences Holdings Business Description
Panacea Life Sciences Holdings Inc is a holding company organized as a plant-based natural health ingredient and product company, specializing in the development, manufacturing, research, and distribution of products and rapidly growing natural health and wellness market segment for both humans and animals. The company also offers the purest natural remedies within its branded product lines for every aspect of life: PANA Health, PANA Beauty, PANA Sport, PANA Pet, PANA Pure and PANA Life.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSH has been successfully added to your 
